Cytovia Therapeutics
Gilles Seydoux is a seasoned professional in the biopharmaceutical and healthcare sectors, currently serving as Co-Founder and Board Director at NAYA Biosciences and Cytovia Therapeutics, as well as Board Member at PROCARE HEALTH. Seydoux holds additional leadership roles as Chairman of the Board at HOLDING CARSEY and Company Owner at GTS Health Consulting. With extensive experience at GSK, including positions such as Global Marketing Director Rare Diseases and Executive Director for various commercial products, Seydoux also has a background at Wyeth Pharmaceuticals. Academic credentials include a Pharm D from Université Paris Cité.
This person is not in the org chart
This person is not in any teams
This person is not in any offices
Cytovia Therapeutics
2 followers
Cytovia is dedicated to the development of transformational cancer immunotherapies, addressing several of the most challenging unmet medical needs including the prevention of cancer relapse and metastasis. Cytovia focuses on Natural Killer (NK) cell biology and applies precision medicine tools to develop the right therapy for the right patient at the right stage of the disease. Cytovia has secured access to multiple advanced technologies, including allogeneic cell therapy, multispecific antibodies, and cytokines. Cytovia establishes development partnerships to accelerate time-to-market and commercialization alliances in order to optimize rapid adoption of its novel immunotherapies.